Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 20/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 11/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 10/20 | 0.63 |
| ▸ | HDAC11 | Q96DB2 | 8/20 | 0.63 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.63 |
| ▸ | HDAC4 | P56524 | 7/20 | 0.63 |
| ▸ | HDAC7 | Q8WUI4 | 7/20 | 0.63 |
| ▸ | HDAC10 | Q969S8 | 7/20 | 0.63 |
| ▸ | HDAC9 | Q9UKV0 | 7/20 | 0.63 |
| ▸ | HDAC5 | Q9UQL6 | 7/20 | 0.63 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | KDM1A | O60341 | 1/20 | 0.63 |
| ▸ | F3 | P13726 | 1/20 | 0.63 |
| ▸ | NAMPT | P43490 | 3/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL2409900 | 0.99 | HDAC1 (0.62) | HDAC1HDAC2HDAC3HDAC11HDAC8 | |
| Hydrochloric Acid SCHEMBL2407989 | 0.99 | HDAC1 (0.62) | HDAC1HDAC2HDAC3HDAC11HDAC8 | |
| SCHEMBL2411926 | 0.91 | HDAC1 (0.62) | HDAC1HDAC2HDAC3HDAC11HDAC8 | |
| SCHEMBL3559032 | 0.89 | HDAC1 (0.62) | HDAC1HDAC2HDAC3HDAC11HDAC8 | |
| SCHEMBL2412810 | 0.89 | HDAC1 (0.55) | HDAC1HDAC2HDAC3HDAC11HDAC8 | |
| SCHEMBL2413630 | 0.88 | HDAC1 (0.66) | HDAC1HDAC2HDAC3HDAC11HDAC8 | |
| SCHEMBL2416256 | 0.88 | HDAC1 (0.66) | HDAC1HDAC2HDAC3HDAC11HDAC8 | |
| SCHEMBL2411259 | 0.88 | HDAC1 (0.56) | HDAC1HDAC2HDAC3HDAC11HDAC8 | |
| SCHEMBL2416730 | 0.87 | HDAC1 (0.50) | HDAC1HDAC2HDAC3HDAC11HDAC8 | |
| SCHEMBL2410013 | 0.87 | HDAC1 (0.67) | HDAC1HDAC2HDAC3HDAC11HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE45499-E1 | N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-28 | — | — | US | claimed |
| CN-102137846-B | N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275)polymorph B | BAYER SCHERING PHARMA AG | 2014-04-23 | — | — | CN | claimed |
| JP-2012500819-A | — | — | 2012-01-12 | — | — | JP | claimed |
| EP-2350005-B1 | N-(2-AMINOPHENYL)-4-[N-(PYRIDINE-3-YL)-METHOXYCARBONYL-AMINOMETHYL]-BENZAMIDE (MS-275)POLYMORPH B | Bayer Pharma AG (DE) | 2011-12-21 | — | — | EP | claimed |
| EP-2350005-A1 | N-(2-AMINOPHENYL)-4-[N-(PYRIDINE-3-YL)-METHOXYCARBONYL-AMINOMETHYL]-BENZAMIDE (MS-275)POLYMORPH B | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-08-03 | — | — | EP | claimed |
| CN-102137846-A | N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275)polymorph b | BAYER SCHERING PHARMA AG | 2011-07-27 | — | — | CN | claimed |
| US-7973166-B2 | N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B | BAYER SCHERING PHARMA AG (DE) | 2011-07-05 | — | — | US | claimed |
| US-20100056585-A1 | N-(2-Aminophenyl)-4-[N-(Pyridine-3-yl)-Methoxycarbonyl-Aminomethyl]-Benzamide (MS-275) Polymorph B | BAYER SCHERING PHARMA AG (DE) | 2010-03-04 | — | — | US | claimed |
| WO-2010022988-A1 | N-(2-AMINOPHENYL)-4-[N-(PYRIDINE-3-YL)-METHOXYCARBONYL-AMINOMETHYL]-BENZAMIDE (MS-275)POLYMORPH B | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-03-04 | — | — | WO | claimed |
| US-20050215601-A1 | Therapeutic agent for rheumatic disease comprising benzamide derivative as active ingredient | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-09-29 | — | — | US | claimed |
| EP-1547585-A1 | THERAPEUTIC AGENT FOR RHEUMATISM CONTAINING BENZAMIDE DERIVATIVE AS ACTIVE INGREDIENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-06-29 | — | — | EP | claimed |
| US-12168054-B2 | Method of treating cancer using a combination of entinostat and an anti-CSF-1R antibody | SYNDAX PHARMACEUTICALS, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240288425-A1 | SELECTION OF PATIENTS FOR COMBINATION THERAPY | SYNDAX PHARMACEUTICALS, INC. | 2024-08-29 | — | — | US | disclosed |
| US-12000829-B2 | Selection of patients for combination therapy | SYNDAX PHARMACEUTICALS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| EP-3270966-B1 | COMBINATION OF HDAC INHIBITOR AND ANTI-PD-1 ANTIBODY FOR TREATMENT OF CANCER WHEREIN THE COMBINATION DOES NOT COMPRISE 5-AZACYTIDINE. | SYNDAX PHARMACEUTICALS INC (US) | 2024-05-01 | — | — | EP | disclosed |
| WO-2004058234-A2 | PHARMACEUTICAL COMBINATIONS OF PHTHALAZINE VEGF INHIBITORS AND BENZAMIDE HDAC INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-07-15 | — | — | WO | disclosed |
| EP-1437346-A1 | Benzamide derivatives useful as cell differentiation inducers | Schering AG (DE) | 2004-07-14 | — | — | EP | disclosed |
| EP-0847992-B1 | Benzamide derivatives, useful as cell differentiation inducers | SCHERING AG (DE) | 2004-06-23 | — | — | EP | disclosed |
| US-6174905-B1 | AS CARCINOSTATIC AGENT TO A HEMATOLOGIC MALIGNANCY AND A SOLID CARCINOMA | MITSUI CHEMICALS, INC. (JP) | 2001-01-16 | — | — | US | disclosed |
| EP-0847992-A1 | Benzamide derivatives, useful as cell differentiation inducers | Mitsui Chemicals, Inc. (JP) | 1998-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240288425-A1 | SELECTION OF PATIENTS FOR COMBINATION THERAPY | CD14, CD74, HDAC1 | HDAC1 3/4885HDAC2 7/4885HDAC3 6/4885 |
| US-20050215601-A1 | Therapeutic agent for rheumatic disease comprising benzamide derivative as active ingredient | SSB, HRH2, TYR | HDAC1 13/4885HDAC2 17/4885HDAC3 88/4885 |
| US-12000829-B2 | Selection of patients for combination therapy | CD14, CD74, HDAC1 | HDAC1 3/4885HDAC2 7/4885HDAC3 6/4885 |
| US-20100056585-A1 | N-(2-Aminophenyl)-4-[N-(Pyridine-3-yl)-Methoxycarbonyl-Aminomethyl]-Benzamide (MS-275) Polymorph B | CYP3A5, MRPS35, NNMT | HDAC1 482/4885HDAC2 767/4885HDAC3 1186/4885 |
| US-12168054-B2 | Method of treating cancer using a combination of entinostat and an anti-CSF-1R antibody | CSF3R, CSF1R, HDAC1 | HDAC1 3/4885HDAC2 7/4885HDAC3 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.